Tropical Diseases



Discovering, Developing, and Distributing Drugs for Tropical Diseases

60° Pharmaceuticals (60P) was founded with the goal of discovering, developing, and distributing drugs for tropical diseases, including those considered neglected by the World Health Organization. Malaria and tuberculosis are usually included on this list, and despite mature drug development pipelines for these diseases, critical gaps remain. 60P is focused on drug development for therapeutic modalities left unaddressed by the existing research and development networks, and will also invest in products for tropical diseases targeted at developed country market segments in order to improve overall return on investment. 


New Drugs for Malaria Prevention Malaria Prophylaxis

Malaria is a parasitic disease causing 200 million clinical infections and 548,000 deaths annually in endemic countries, and is a constant threat to travelers from other countries who lack any immunity to malaria. Although there is now a reliable supply of artemisinin combination therapies and bed nets to treat malaria and prevent transmission, and a partially effective vaccine is coming, these tools alone are unlikely to allow regional malaria elimination in the near future. In the travel medicine market, existing drugs are only partially adequate because they do not protect against all species of the parasite in all parts of the world or require daily dosing or complicated schedules for post-exposure prophylaxis. A long half-life antimalarial active against all stages of the malaria parasite (gametocytes, hypnozoites, developing liver schizonts and asexual blood stages) could have significant impact on malaria prevalence in combination with existing tools, and be a valuable addition to the available pharmacopoeia for travel medicine.


Malaria Prophylaxis
  • Over 3 billion people live in areas at risk of malaria transmission in 106 countries and territories
    • Annually over 195 million cases and more than 580,000 deaths
  • 125 million travelers to endemic regions per annum
    • 10,000-plus reported traveler cases of malaria
    • Prophylactics utilized by 78% Europeans, 48% USA
    • US $270 million per annum in sales of malaria prophylactic drugs
  • Market potential for tafenoquine for malaria prophylaxis in USA, Europe, UK, Canada, Australia – $70 million per annum


 World Distribution of Malaria

Unmet Medical Need for Dengue Drugs

Dengue is a viral disease transmitted by mosquitoes. 2.5 billion people are at risk and there are an estimated 96 million symptomatic cases every year. Mild dengue may progress to a hemorrhagic form and cause death. The economic burden of clinical cases based on 2006 data has been estimated to be $1.7 billion per annum while potential drug sales assuming 100 percent market share are estimated to be $338 million per annum. However, these are likely to be underestimates given the recent report suggesting that the incidence of dengue may be three-fold higher than previously assumed. The current standard of care is fever and pain relief and transfer to ICUs. Dengue vaccines are coming, but supply constraints, cost, and other factors may limit their impact. Dengue drugs would complement the use of dengue vaccines by public health systems, provide relief to dengue patients, and substantially reduce economic costs associated with the disease.


Dengue Fever Treatment
  • 2.5 billion people at risk, infects nearly 400 million people annually with ~100 million of those infections being symptomatic
    • 2 million to 3 million severe cases and 25,000 deaths per year
  • Economic burden per annum $12 billion; incidences have increased with alarming pace and expanded regions are affected
  • Dengue vaccine approved in Brazil, Mexico, and Philippines is only partially effective
  • No therapeutics are available to treat symptomatic disease



 World Distribution of Dengue






About  |  Tropical Diseases  |  Products  |  Research  |  Responsibility  |  Investors  |  Media  |  Careers  |  Contact 

 1025 Connecticut Avenue NW, Suite 1000   Washington, DC 20036 
Phone: 1-240-351-1167   Email: inquiries@60degreespharma.com 

 Content © 2017. 60° Pharmaceuticals, LLC. All rights reserved.